Literature DB >> 14666366

Plasminogen kringle 5 reduces vascular leakage in the retina in rat models of oxygen-induced retinopathy and diabetes.

S X Zhang1, J Sima, C Shao, J Fant, Y Chen, B Rohrer, G Gao, J-x Ma.   

Abstract

AIMS/HYPOTHESIS: Retinal vascular leakage is an early pathological feature in diabetic retinopathy and can lead to macular oedema and loss of vision. Previously we have shown that plasminogen kringle 5 (K5), an angiogenic inhibitor, inhibits retinal neovascularisation in the rat model of oxygen-induced retinopathy (OIR). The purpose of this study was to examine the effect of K5 on vascular leakage in the retina.
METHODS: Neonatal rats were exposed to hyperoxia to induce OIR. Diabetes was induced in adult rats by injecting streptozotocin. Vascular permeability was measured by Evans blue method. Expression of vascular endothelial growth factor (VEGF) was evaluated using immunohistochemistry and western blot analysis.
RESULTS: Rats with OIR and diabetes showed abnormal vascular hyperpermeability in the retina and iris. Intravitreal injection of K5, reduced vascular permeability in both animal models, but did not affect permeability in normal rats. K5 reduced vascular permeability at doses substantially lower than that required for inhibition of retinal neovascularisation. The K5-induced reduction in vascular permeability correlated with its down-regulation of VEGF expression in the retina. Moreover, K5 inhibited IGF-1-induced hyperpermeability, which is known to arise through up-regulation of endogenous VEGF expression. However, K5 had no effect on the hyperpermeability induced by injection of exogenous VEGF. CONCLUSIONS/
INTERPRETATION: Very low doses of K5 reduce pathological vascular leakage in the retina. K5 thus has therapeutic potential in the treatment of diabetic macular oedema. This effect can be ascribed, at least in part, to the down-regulation of endogenous VEGF expression.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14666366     DOI: 10.1007/s00125-003-1276-4

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  38 in total

1.  Clinical trials referral resource. Current clinical trials administering the antiangiogenesis agent SU5416.

Authors:  L E Via; R E Gore-Langton; J M Pluda
Journal:  Oncology (Williston Park)       Date:  2000-09       Impact factor: 2.990

2.  Intravitreal injection of plasminogen kringle 5, an endogenous angiogenic inhibitor, arrests retinal neovascularization in rats.

Authors:  D Zhang; P L Kaufman; G Gao; R A Saunders; J X Ma
Journal:  Diabetologia       Date:  2001-06       Impact factor: 10.122

Review 3.  Preclinical safety evaluation of rhuMAbVEGF, an antiangiogenic humanized monoclonal antibody.

Authors:  A M Ryan; D B Eppler; K E Hagler; R H Bruner; P J Thomford; R L Hall; G M Shopp; C A O'Neill
Journal:  Toxicol Pathol       Date:  1999 Jan-Feb       Impact factor: 1.902

4.  Down-regulation of vascular endothelial growth factor and up-regulation of pigment epithelium-derived factor: a possible mechanism for the anti-angiogenic activity of plasminogen kringle 5.

Authors:  Guoquan Gao; Yan Li; Stephen Gee; Andrew Dudley; James Fant; Craig Crosson; Jian-xing Ma
Journal:  J Biol Chem       Date:  2002-01-08       Impact factor: 5.157

5.  Prevention of leukostasis and vascular leakage in streptozotocin-induced diabetic retinopathy via intercellular adhesion molecule-1 inhibition.

Authors:  K Miyamoto; S Khosrof; S E Bursell; R Rohan; T Murata; A C Clermont; L P Aiello; Y Ogura; A P Adamis
Journal:  Proc Natl Acad Sci U S A       Date:  1999-09-14       Impact factor: 11.205

6.  Structure and ligand binding determinants of the recombinant kringle 5 domain of human plasminogen.

Authors:  Y Chang; I Mochalkin; S G McCance; B Cheng; A Tulinsky; F J Castellino
Journal:  Biochemistry       Date:  1998-03-10       Impact factor: 3.162

7.  Oxygen-induced retinopathy in the mouse.

Authors:  L E Smith; E Wesolowski; A McLellan; S K Kostyk; R D'Amato; R Sullivan; P A D'Amore
Journal:  Invest Ophthalmol Vis Sci       Date:  1994-01       Impact factor: 4.799

8.  Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization.

Authors:  E A Pierce; R L Avery; E D Foley; L P Aiello; L E Smith
Journal:  Proc Natl Acad Sci U S A       Date:  1995-01-31       Impact factor: 11.205

9.  The relation between expression of vascular endothelial growth factor and breakdown of the blood-retinal barrier in diabetic rat retinas.

Authors:  T Murata; K Nakagawa; A Khalil; T Ishibashi; H Inomata; K Sueishi
Journal:  Lab Invest       Date:  1996-04       Impact factor: 5.662

10.  Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders.

Authors:  L P Aiello; R L Avery; P G Arrigg; B A Keyt; H D Jampel; S T Shah; L R Pasquale; H Thieme; M A Iwamoto; J E Park
Journal:  N Engl J Med       Date:  1994-12-01       Impact factor: 91.245

View more
  21 in total

1.  Bacillus cereus-induced permeability of the blood-ocular barrier during experimental endophthalmitis.

Authors:  Andrea L Moyer; Raniyah T Ramadan; Billy D Novosad; Roger Astley; Michelle C Callegan
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-03-05       Impact factor: 4.799

2.  Anti-inflammatory and antiangiogenic effects of nanoparticle-mediated delivery of a natural angiogenic inhibitor.

Authors:  Ji Jin; Kevin K Zhou; Kyoungmin Park; Yang Hu; Xun Xu; Zhi Zheng; Puneet Tyagi; Uday B Kompella; Jian-xing Ma
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-08-05       Impact factor: 4.799

3.  Nanoparticle-mediated expression of an angiogenic inhibitor ameliorates ischemia-induced retinal neovascularization and diabetes-induced retinal vascular leakage.

Authors:  Kyoungmin Park; Ying Chen; Yang Hu; Aaron S Mayo; Uday B Kompella; Richard Longeras; Jian-xing Ma
Journal:  Diabetes       Date:  2009-06-02       Impact factor: 9.461

4.  Pathophysiological characteristics of diabetic ocular complications in spontaneously diabetic torii rat.

Authors:  Tomohiko Sasase
Journal:  J Ophthalmol       Date:  2010-05-25       Impact factor: 1.909

5.  The potential of nanomedicine therapies to treat neovascular disease in the retina.

Authors:  Krysten M Farjo; Jian-Xing Ma
Journal:  J Angiogenes Res       Date:  2010-10-08

6.  Pigment epithelium-derived factor mitigates inflammation and oxidative stress in retinal pericytes exposed to oxidized low-density lipoprotein.

Authors:  Sarah X Zhang; Joshua J Wang; Azar Dashti; Kenneth Wilson; Ming-Hui Zou; Luke Szweda; Jian-Xing Ma; Timothy J Lyons
Journal:  J Mol Endocrinol       Date:  2008-06-27       Impact factor: 5.098

7.  Endoplasmic reticulum stress is implicated in retinal inflammation and diabetic retinopathy.

Authors:  Jingming Li; Joshua J Wang; Qiang Yu; Min Wang; Sarah X Zhang
Journal:  FEBS Lett       Date:  2009-04-11       Impact factor: 4.124

8.  Poly(ADP-Ribose) Polymerase-1 (PARP-1) Inhibitors Reduce Reactive Gliosis and Improve Angiostatin Levels in Retina of Diabetic Rats.

Authors:  Mykhailo M Guzyk; Artem A Tykhomyrov; Victor S Nedzvetsky; Irina V Prischepa; Tatiana V Grinenko; Lesya V Yanitska; Tamara M Kuchmerovska
Journal:  Neurochem Res       Date:  2016-06-02       Impact factor: 3.996

Review 9.  Mass spectrometric quantification of amino acid oxidation products identifies oxidative mechanisms of diabetic end-organ damage.

Authors:  Anuradha Vivekanadan-Giri; Jeffrey H Wang; Jaeman Byun; Subramaniam Pennathur
Journal:  Rev Endocr Metab Disord       Date:  2008-12       Impact factor: 6.514

10.  Reactive oxygen species mediate a cellular 'memory' of high glucose stress signalling.

Authors:  M A Ihnat; J E Thorpe; C D Kamat; C Szabó; D E Green; L A Warnke; Z Lacza; A Cselenyák; K Ross; S Shakir; L Piconi; R C Kaltreider; A Ceriello
Journal:  Diabetologia       Date:  2007-05-17       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.